The co-founder of the startup Ousia Pharma describes working from Copenhagen's BioInnovation Institute on his company's next-generation enhancer to GLPs

Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company. Plus, why Ousia is conjugating NMDAs to GLPs in an attempt to improve their utility through enhanced neuroplasticity.